Network mirroring for drug repositioning

BackgroundAlthough drug discoveries can provide meaningful insights and significant enhancements in pharmaceutical field, the longevity and cost that it takes can be extensive where the success rate is low. In order to circumvent the problem, there has been increased interest in ‘Drug Repositioning’ where one searches for already approved drugs that have high potential of efficacy when applied to other diseases. To increase the success rate for drug repositioning, one considers stepwise screening and experiments based on biological reactions. Given the amount of drugs and diseases, however, the one-by-one procedure may be time consuming and expensive.MethodsIn this study, we propose a machine learning based approach for efficiently selecting candidate diseases and drugs. We assume that if two diseases are similar, then a drug for one disease can be effective against the other disease too. For the procedure, we first construct two disease networks; one with disease-protein association and the other with disease-drug information. If two networks are dissimilar, in a sense that the edge distribution of a disease node differ, it indicates high potential for repositioning new candidate drugs for that disease. The Kullback-Leibler divergence is employed to measure difference of connections in two constructed disease networks. Lastly, we perform repositioning of drugs to the top 20% ranked diseases.ResultsThe results showed that F-measure of the proposed method was 0.75, outperforming 0.5 of greedy searching for the entire diseases. For the utility of the proposed method, it was applied to dementia and verified 75% accuracy for repositioned drugs assuming that there are not any known drugs to be used for dementia.ConclusionThis research has novelty in that it discovers drugs with high potential of repositioning based on disease networks with the quantitative measure. Through the study, it is expected to produce profound insights for possibility of undiscovered drug repositioning.

[1]  Hyunjung Shin,et al.  CLASH: Complementary Linkage with Anchoring and Scoring for Heterogeneous biomolecular and clinical data , 2016, BMC Medical Informatics and Decision Making.

[2]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[3]  P. Jaccard Distribution de la flore alpine dans le bassin des Dranses et dans quelques régions voisines , 1901 .

[4]  A. V. Grimstone Molecular biology of the cell (3rd edn) , 1995 .

[5]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[6]  Evgueni A. Haroutunian,et al.  Information Theory and Statistics , 2011, International Encyclopedia of Statistical Science.

[7]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[8]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[9]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[10]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[11]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[12]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[13]  Hyunjung Shin,et al.  Research and applications: Breast cancer survivability prediction using labeled, unlabeled, and pseudo-labeled patient data , 2013, J. Am. Medical Informatics Assoc..

[14]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[15]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[16]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[17]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[18]  Pankaj Agarwal,et al.  A Pathway-Based View of Human Diseases and Disease Relationships , 2009, PloS one.

[19]  Xia Li,et al.  The expanded human disease network combining protein–protein interaction information , 2011, European Journal of Human Genetics.

[20]  I. Milsom,et al.  The prevalence of urinary incontinence , 2000, Acta obstetricia et gynecologica Scandinavica.

[21]  R. Basha,et al.  Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies , 2015, Journal of Neurochemistry.

[22]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[23]  E. Finger New Potential Therapeutic Approaches in Frontotemporal Dementia: Oxytocin, Vasopressin, and Social Cognition , 2011, Journal of Molecular Neuroscience.

[24]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[25]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[26]  Alexander Zien,et al.  Semi-Supervised Learning , 2006 .

[27]  I. Khanna,et al.  Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.

[28]  N. Campbell Genetic association database , 2004, Nature Reviews Genetics.

[29]  Xin Chen,et al.  DCDB 2.0: a major update of the drug combination database , 2014, Database J. Biol. Databases Curation.

[30]  Tatiana A. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..

[31]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[32]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[33]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[34]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[35]  Darcy A. Davis,et al.  Exploring and Exploiting Disease Interactions from Multi-Relational Gene and Phenotype Networks , 2011, PloS one.

[36]  Joel Dudley,et al.  Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..

[37]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[38]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[39]  Weida Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[40]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[41]  Huaiyu Zhu On Information and Sufficiency , 1997 .

[42]  Ehud Weinstein,et al.  Sequential algorithms for parameter estimation based on the Kullback-Leibler information measure , 1990, IEEE Trans. Acoust. Speech Signal Process..

[43]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[44]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..

[45]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[46]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[47]  David S. Wishart,et al.  T3DB: a comprehensively annotated database of common toxins and their targets , 2009, Nucleic Acids Res..

[48]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[49]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.